UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma

Expert review of anticancer therapy, 2022-05, Vol.22 (5), p.449-455

2022

Volltextzugriff (PDF)

Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma

Cancer, 2019-12, Vol.125 (23), p.4148-4157

2019

Volltextzugriff (PDF)

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin

Blood, 2017-06, Vol.129 (25), p.3379-3385

2017

Volltextzugriff (PDF)

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3088-3094

2020

Volltextzugriff (PDF)

Immunotherapy Toxicity

Hematology/oncology clinics of North America, 2019-04, Vol.33 (2), p.275-290

2019

Volltextzugriff (PDF)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical cancer research, 2021-12, Vol.27 (24), p.6687-6695

2021

Volltextzugriff (PDF)

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Melanoma research, 2022-02, Vol.32 (1), p.35-44

2022

Volltextzugriff (PDF)

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003743

2021

Volltextzugriff (PDF)

Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2551-2551

2021

Volltextzugriff (PDF)

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for immunotherapy of cancer, 2024-07, Vol.12 (7), p.e009495

2024

Volltextzugriff (PDF)

Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma

Journal for immunotherapy of cancer, 2020-11, Vol.8 (2), p.e001467

2020

Volltextzugriff (PDF)

Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008215

2024

Volltextzugriff (PDF)

Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism

Research and practice in thrombosis and haemostasis, 2020-07, Vol.4 (5), p.860-865

2020

Volltextzugriff (PDF)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

BJUI compass, 2022-03, Vol.3 (2), p.169-172

2022

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2021-08, Vol.206 (2), p.250-251

2021

Volltextzugriff (PDF)

VEGF and PD-1 pathway inhibitors in renal cell carcinoma

Cancer, 2019-09, Vol.125 (23), p.4148-4157

2019

Volltextzugriff (PDF)

Transdermal oestrogen for advanced prostate cancer

The Lancet (British edition), 2021-02, Vol.397 (10274), p.556-557

2021

Volltextzugriff (PDF)

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS4618-TPS4618

2024

Volltextzugriff (PDF)

Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4544-4544

2022

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2021-08, Vol.206 (2), p.250-251

2021

Volltextzugriff (PDF)

Association between tumor mutational burden (TMB) and immune-related adverse events (irAEs) in patients (pts) with metastatic urothelial carcinoma (mUC) during checkpoint immunotherapy

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.489-489

2021

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2021-05, p.101097JU000000000000176801

2021

Volltextzugriff (PDF)

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS588-TPS588

2022

Volltextzugriff (PDF)

Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.565-565

2022

Volltextzugriff (PDF)

Association of enfortumab vedotin (EV) toxicity with baseline parameters and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16585-e16585

2023

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Oncology
(16)
Humans
(11)
Immunotherapy
(8)
Female
(5)
Male
(5)
Aged
(4)
Chemotherapy
(4)
Immune Checkpoint Inhibitors
(4)
Immune Checkpoint Inhibitors - Therapeutic Use
(4)
Immunology
(4)
Metastasis
(4)
Middle Aged
(4)
Survival Analysis
(4)
Toxicity
(4)
Tumors
(4)
Adult
(3)
Aged, 80 And Over
(3)
Biomarkers
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma

Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Immunotherapy Toxicity

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma

Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer

Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

Editorial Comment

VEGF and PD-1 pathway inhibitors in renal cell carcinoma

Transdermal oestrogen for advanced prostate cancer

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO)

Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs)

Editorial Comment

Association between tumor mutational burden (TMB) and immune-related adverse events (irAEs) in patients (pts) with metastatic urothelial carcinoma (mUC) during checkpoint immunotherapy

Editorial Comment

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial

Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC)

Association of enfortumab vedotin (EV) toxicity with baseline parameters and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC)

Suchergebnisse filtern